Geron to Present First Real-World RYTELO Data at EHA 2026 Congress
Geron Corporation will present the first real-world evidence study of RYTELO (imetelstat) in lower-risk myelodysplastic syndrome patients at the EHA 2026 Congress. The retrospective analysis will provide patient-level data on RYTELO’s safety and efficacy beyond clinical trials.
1. Upcoming EHA 2026 Presentation
Geron will unveil the inaugural real-world evidence study of RYTELO (imetelstat) in patients with lower-risk myelodysplastic syndromes at the European Hematology Association 2026 Congress. This retrospective analysis aims to deliver patient-level insights on treatment safety and efficacy in a broader clinical setting, potentially informing future regulatory filings and commercial strategies.
Related News
BMY
Bristol-Myers Squibb Deploys Anthropic Claude AI to 30,000 Employees for Drug Discovery
BMY•
AMD
AMD Shares Double in 2026 as Data Center Revenue Jumps 57%
AMD•
AMPG
AmpliTech Gains FCC and Canadian 5G DAS Approval, Shares Jump 14%
AMPG•
FMS
Fresenius Medical Care Reappoints CFO Martin Fischer for Five-Year Term to 2031
FMS•
KLAC
Bernstein Raises KLA Price Target to $1,975 on Strong WFE Forecasts
KLAC•
Sources
F